Shannon McWeeney, Ph.D., works at the intersection of computer science, biostatistics, genetics and medicine, finding ways to speed cancer research past the bottlenecks stalling progress. She’s...
Like few other drugs in the history of oncology, Gleevec transformed the outlook for patients: a disease with a life expectancy of less than five years – chronic myeloid leukemia – became a...
Medicine had never seen anything like it before, Brian Druker, M.D., recalled. "These are people who’d been told to get their affairs in order. And now their blood counts are normal," the...
Understanding the earliest drivers of cancer formation can lead to less toxic and more effective treatments. It transformed the outlook for people diagnosed with chronic myeloid leukemia. A...
The depth of remission achieved with the targeted therapy imatinib (Gleevec) raises a tough new question for some leukemia patients: is it ever safe to stop taking the breakthrough drug developed at...
Average life expectancy had been no better than 18 months for people diagnosed with advanced gastrointestinal stromal tumors, or GISTs. The outlook changed dramatically in 2001 with the arrival...
Life expectancy in patients with chronic myeloid leukemia has soared to a level almost equal to that of the general population, according to a Swedish study quantifying the life-saving impact of...